LYNPARZA® Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient -Positive Advanced Ovarian Cancer Pharmaceutical Investing
Pfizer to Supply Global Fund Up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries Pharmaceutical Investing
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology Convergence 2022 Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts Pharmaceutical Investing
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection Pharmaceutical Investing
Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area Pharmaceutical Investing
Aurinia Announces European Commission Approval of LUPKYNIS® for the Treatment of Lupus Nephritis Pharmaceutical Investing
